MissionIR Articles
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial…
-
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb.…
-
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35…
-
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year…
-
MissionIRNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology…
-
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to…
Search Articles
Latest Articles
- MissionIRNewsBreaks – USA Rare Earth, Inc. (Nasdaq: USAR) to Acquire Texas Mineral Resources (OTCQB: TMRC) in $73M Stock Deal
- MissionIRNewsBreaks – Standex International Corporation (NYSE: SXI) Divests Federal Industries Business for Approximately $70M
- MissionIRNewsBreaks – FG Nexus Inc. (NASDAQ: FGNX, FGNXP) Ranked Top SPAC Sponsor by Median Returns in EarlyBirdCapital Study
- Trilogy Metals Inc.’s Joint Venture, Ambler Metals, Strengthens Management as U.S. Mineral Policy Gains Momentum
- MissionIRNewsBreaks – Pelican Acquisition Corp. (NASDAQ: PELI) Announces Ashiq Merchant as CFO of Post-Merger Greenland Energy